Docetaxel Re-challenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review

Tarek Assi 1 2Elie Rassy 3Fadi Farhat 3 4Clarisse Kattan 3Joseph Kattan 3

Affiliations

1Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon, tarekassi@gmail.com.

2Oncology Department, Hammoud Hospital UMC, Saida, Lebanon, tarekassi@gmail.com.

3Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

4Oncology Department, Hammoud Hospital UMC, Saida, Lebanon.

PMID: 32380503

DOI: 10.1159/000506693

Abstract

Background: Recent years have witnessed a huge shift in the management and prognosis of metastatic prostate cancer with the advent of new-generation anti-hormonal treatments. Docetaxel, which was initially approved in the castrate-resistant prostate cancer setting, has been approved in the earlier course of the disease as it is still castrate sensitive.

Summary: Apart from cabazitaxel and in the absence of other effective chemotherapies, docetaxel rechallenge (DR) in patients with proved sensitivity to docetaxel in the earlier stage of the disease remains a possible option. Unfortunately, the pivotal trials rarely reported on the outcomes of docetaxel retreatment which seems a plausible option in patients initially responding to docetaxel and maintaining a minimum progression-free interval of 3-6 months. In this review, a summary of the clinical evidence and potential concerns for the use of DR in patients with metastatic prostate cancer will be presented. Key Messages: Pivotal trials of docetaxel in metastatic castrate-sensitive prostate cancer as well as metastatic castrate-resistant prostate cancer have not reported on the outcomes of DR except in the GETUG-AFU 15 trial where the outcomes were disappointing. Based on the published retrospective data, DR may be effective in patients who initially responded to docetaxel and maintained a progression-free interval exceeding 6 months.

Keywords: Castrate resistant; Castrate sensitive; Docetaxel; Prostate cancer; Rechallenge.